



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 4, 2011

Raafit E. F. Fahim, Ph.D.  
Chief Executive Officer  
Nabi Biopharmaceuticals  
12276 Wilkins Avenue  
Rockville, MD 20852

**Re:   Nabi Biopharmaceuticals**  
**Form 10-K for the Fiscal Year Ended December 26, 2009**  
**Form 10-Q for the Quarterly Period Ended September 25, 2010**  
**File No. 000-04829**

Dear Dr. Fahim:

We have completed our review of your filings and do not have any further comments at this time.

Sincerely,

Joel Parker  
Accounting Branch Chief